BR112016024458A2 - antígeno e do hepadnavírus marcado e seu uso em triagem de substâncias antivirais - Google Patents
antígeno e do hepadnavírus marcado e seu uso em triagem de substâncias antiviraisInfo
- Publication number
- BR112016024458A2 BR112016024458A2 BR112016024458A BR112016024458A BR112016024458A2 BR 112016024458 A2 BR112016024458 A2 BR 112016024458A2 BR 112016024458 A BR112016024458 A BR 112016024458A BR 112016024458 A BR112016024458 A BR 112016024458A BR 112016024458 A2 BR112016024458 A2 BR 112016024458A2
- Authority
- BR
- Brazil
- Prior art keywords
- hepadnavirus
- antigen
- labeled
- screening
- hepatitis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
- C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção refere-se a métodos e usos para triagem de substâncias anti-hepadnavirais, em que as substâncias são triadas para a capacidade para inibir dna circular fechado de modo covalente (ccc) de um hepadnavírus, como o vírus da hepatite b. os métodos e usos tiram proveito de células compreendendo uma sequência de ácido nucleico que codifica um antígeno e do hepadnavírus marcado, como o antígeno e do vírus da hepatite b (hbeag). além disso, a presente invenção proporciona sequências de ácido nucleico que codificam um antígeno e do hepadnavírus marcado e proteínas codificadas pelas mesmas. além disso, são proporcionados kits para uso nos métodos de triagem.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462014996P | 2014-06-20 | 2014-06-20 | |
| PCT/EP2015/063838 WO2015193484A1 (en) | 2014-06-20 | 2015-06-19 | Tagged hepadnavirus e antigen and its use in screening antiviral substances |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016024458A2 true BR112016024458A2 (pt) | 2017-10-10 |
Family
ID=53498969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016024458A BR112016024458A2 (pt) | 2014-06-20 | 2015-06-19 | antígeno e do hepadnavírus marcado e seu uso em triagem de substâncias antivirais |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10072047B2 (pt) |
| EP (2) | EP3157944B1 (pt) |
| JP (1) | JP6543338B2 (pt) |
| KR (1) | KR102309355B1 (pt) |
| CN (1) | CN106716128B (pt) |
| BR (1) | BR112016024458A2 (pt) |
| CA (1) | CA2943047C (pt) |
| MX (1) | MX2016014359A (pt) |
| RU (1) | RU2711750C2 (pt) |
| WO (1) | WO2015193484A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108611395A (zh) * | 2016-12-12 | 2018-10-02 | 中山大学 | 一种抗人乙肝病毒药物的筛选方法 |
| CN107022543A (zh) * | 2017-05-25 | 2017-08-08 | 郑州市第六人民医院 | 一种提取乙型肝炎病毒核酸用磁珠、提取试剂、提取方法、定量检测用试剂盒 |
| WO2020072207A1 (en) * | 2018-10-04 | 2020-04-09 | The Rockefeller University | Rna-based methods to launch hepatitis b virus infection |
| KR20220095183A (ko) * | 2019-08-29 | 2022-07-06 | 지 테크 바이오 엘엘씨 | 바이러스 감염을 치료하기 위한 조성물 및 방법 |
| US20230323369A1 (en) * | 2020-06-24 | 2023-10-12 | Xiamen University | Screening model and method for hbv cccdna-targeting drug |
| CN113293179A (zh) * | 2021-05-10 | 2021-08-24 | 武汉科技大学 | 一种靶向敲除HBx蛋白的质粒及其构建方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5491084A (en) | 1993-09-10 | 1996-02-13 | The Trustees Of Columbia University In The City Of New York | Uses of green-fluorescent protein |
| CN101104867A (zh) * | 2006-07-10 | 2008-01-16 | 中国人民解放军第四军医大学 | 检测乙型肝炎病毒cccDNA的巢式-实时定量PCR方法 |
| BR112014029697A2 (pt) * | 2012-06-01 | 2017-08-08 | Baruch S Blumberg Inst | método para modular a transcrição de cccdna de hepatite b em um indivíduo, método para modular dna circular covalentemente fechado de vírus da hepatite b e composto |
-
2015
- 2015-06-19 BR BR112016024458A patent/BR112016024458A2/pt not_active Application Discontinuation
- 2015-06-19 EP EP15733379.0A patent/EP3157944B1/en active Active
- 2015-06-19 KR KR1020167035519A patent/KR102309355B1/ko active IP Right Grant
- 2015-06-19 MX MX2016014359A patent/MX2016014359A/es active IP Right Grant
- 2015-06-19 EP EP19158753.4A patent/EP3521303A1/en active Pending
- 2015-06-19 CA CA2943047A patent/CA2943047C/en active Active
- 2015-06-19 CN CN201580032914.9A patent/CN106716128B/zh active Active
- 2015-06-19 RU RU2016152429A patent/RU2711750C2/ru active
- 2015-06-19 JP JP2017518599A patent/JP6543338B2/ja active Active
- 2015-06-19 WO PCT/EP2015/063838 patent/WO2015193484A1/en active Application Filing
- 2015-06-19 US US15/309,680 patent/US10072047B2/en active Active
-
2018
- 2018-05-16 US US15/981,316 patent/US10214567B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2943047A1 (en) | 2015-12-23 |
| RU2016152429A (ru) | 2018-07-23 |
| US10072047B2 (en) | 2018-09-11 |
| US10214567B2 (en) | 2019-02-26 |
| EP3521303A1 (en) | 2019-08-07 |
| RU2016152429A3 (pt) | 2019-02-27 |
| JP6543338B2 (ja) | 2019-07-10 |
| CN106716128B (zh) | 2020-06-23 |
| CA2943047C (en) | 2023-03-14 |
| EP3157944A1 (en) | 2017-04-26 |
| CN106716128A (zh) | 2017-05-24 |
| MX2016014359A (es) | 2017-06-12 |
| KR102309355B1 (ko) | 2021-10-06 |
| US20180312546A1 (en) | 2018-11-01 |
| WO2015193484A1 (en) | 2015-12-23 |
| US20170240600A1 (en) | 2017-08-24 |
| EP3157944B1 (en) | 2019-10-09 |
| JP2017518081A (ja) | 2017-07-06 |
| KR20170068411A (ko) | 2017-06-19 |
| RU2711750C2 (ru) | 2020-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016024458A2 (pt) | antígeno e do hepadnavírus marcado e seu uso em triagem de substâncias antivirais | |
| CO2019006541A2 (es) | Administración viral de neoantígenos | |
| CO2018012415A2 (es) | Proteínas de unión específica y usos de las mismas | |
| CY1123932T1 (el) | Δομες πολυειδικου αντισωματος | |
| CY1121934T1 (el) | Αντισωματα anti-fcrn | |
| AR129651A2 (es) | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos | |
| CO2019000395A2 (es) | Genes de mini–distrofina optimizados y casetes de expresión y su uso | |
| BR112018074463A2 (pt) | anticorpos anti-tim-3 e métodos de uso dos mesmos. | |
| EA201690529A1 (ru) | Способы модификации клетки-хозяина | |
| PE20191842A1 (es) | Vectores de neoantigeno de alfavirus | |
| BR112018008051A2 (pt) | vacinas de ácido nucleico para vírus de varicella zoster (vzv) | |
| EA201792420A1 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
| BR112019000512A2 (pt) | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit | |
| BR112017025564A2 (pt) | anticorpos anti-ctla-4 e métodos de uso dos mesmos | |
| BR112018003186A2 (pt) | anticorpos anti-pd-1 e seus métodos de uso | |
| EA201590488A1 (ru) | Способы модификации клеток-хозяев | |
| BR112018006547A2 (pt) | anticorpos de pd-1 e usos dos mesmos | |
| BR112017014917A2 (pt) | elementos regulatórios pós-transcricionais modificados de hepatite | |
| PE20151613A1 (es) | Construcciones de anticuerpos para cdh19 y cd3 | |
| UY35456A (es) | Moléculas de unión para bcma y cd3 | |
| CR20150258A (es) | Anticuerpos anti-ceacam5 y usos de éstos | |
| CY1121964T1 (el) | Αντισωματα εναντιον toy csf-1r | |
| AR091024A1 (es) | Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos | |
| CL2017002514A1 (es) | Anticuerpos anti-c1s humanizados y métodos para usarlos. | |
| CO2018012513A2 (es) | Anticuerpos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |